Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

CD109 expression in basal-like breast carcinoma.

Masaki Hasegawa1, Suzuko Moritani, Yoshiki Murakumo

  • 1Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Pathology International
|April 24, 2008
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.

Nature communications·2026
Same author

Iron-catalyzed oxidative stress reveals an exposome-related ferroptosis-resistant karyomegalic niche in BRCA1-linked renal carcinogenesis.

Redox biology·2026
Same author

Compressive stress inhibits proliferation in AsPC-1 pancreatic cancer cells and reduction of Myc protein.

PloS one·2026
Same author

Possible involvement of the mesenchymal cell marker Meflin in regeneration after retinal injury.

Scientific reports·2026
Same author

CCL5 enhances invasion of squamous cell carcinoma via syndecan-1-dependent ERK signaling.

Cell structure and function·2026
Same author

Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease.

The Journal of clinical investigation·2026

CD109 is identified as a novel diagnostic marker for basal-like breast carcinoma (BLC), a triple-negative subtype. This study found CD109 expression in 60% of BLC cases, distinguishing them from other invasive ductal carcinomas and potentially impacting cancer cell properties.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunohistochemistry

Background:

  • Breast cancer heterogeneity necessitates subtype-specific diagnostics.
  • Basal-like breast carcinoma (BLC) is a triple-negative subtype lacking ER, PgR, and HER2.
  • CD109, a GPI-anchored cell surface protein, is a newly identified breast myoepithelial marker.

Purpose of the Study:

  • To investigate CD109 expression in invasive ductal carcinomas (IDC).
  • To evaluate CD109 as a potential diagnostic marker for BLC.
  • To explore the association between CD109 expression and BLC characteristics.

Main Methods:

  • Immunohistochemistry was performed on 88 formalin-fixed, paraffin-embedded breast carcinoma sections.
  • Antibodies used included anti-CD109, anti-cytokeratin 5/6 (CK5/6), anti-calponin, anti-vimentin, and anti-p63.

More Related Videos

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad
07:05

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Related Experiment Videos

Last Updated: Jul 5, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad
07:05

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

  • BLC and non-BLC subtypes were classified based on gene expression and receptor status.

    • Main Results:

    • CD109 expression was detected in 60% (18/30) of BLC cases.
    • CD109 was not found in 53 ER, PgR, and/or HER2-positive IDC (non-BLC) cases.
    • CD109 positivity in BLC was associated with reduced fat invasion, unlike CK5/6 positivity.

    Conclusions:

    • CD109 is a valuable diagnostic marker for basal-like breast carcinoma.
    • CD109 expression may influence the biological behavior of breast cancer cells.
    • Further research into CD109's role in BLC pathogenesis is warranted.